{"id":24842,"date":"2021-12-14T14:26:07","date_gmt":"2021-12-14T14:26:07","guid":{"rendered":"https:\/\/todaysveterinarypractice.com\/?p=24842"},"modified":"2025-10-06T13:03:04","modified_gmt":"2025-10-06T13:03:04","slug":"clinical-approach-to-proteinuria","status":"publish","type":"post","link":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/urology-renal-medicine\/clinical-approach-to-proteinuria\/","title":{"rendered":"When Urine Trouble: A Clinical Approach to Proteinuria"},"content":{"rendered":"<p class=\"p1\"><span class=\"s1\">The clinical significance of proteinuria is evident in dogs with a severe protein-losing nephropathy (<a href=\"https:\/\/todaysveterinarypractice.com\/dietary-elimination-trial-in-a-dog-with-protein-losing-nephropathy\/\">PLN<\/a>). Consider Pickles, a 7-year-old male castrated cockapoo that presented for abdominal distention, difficulty breathing, and anorexia (<strong>F<\/strong><\/span><strong><span class=\"s2\">IGURE 1<\/span><\/strong><span class=\"s1\">). Pickles was found to have bicavitary effusion and diagnosed with a severe PLN (urine protein:creatinine ratio [UPCR] 28.5, albumin 0.7 g\/dL). Dogs with PLN, such as Pickles, have been shown to have a poor prognosis, with most succumbing to chronic kidney disease (CKD) or thromboembolic complications.<sup>1<\/sup><\/span><\/p>\n<div id=\"attachment_24799\" style=\"width: 460px\" class=\"wp-caption aligncenter\"><a href=\"https:\/\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2021\/12\/Schmid_TVPJanFeb22_Proteinuria_Fig1.png\"><img fetchpriority=\"high\" decoding=\"async\" aria-describedby=\"caption-attachment-24799\" class=\" wp-image-24799\" src=\"https:\/\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2021\/12\/Schmid_TVPJanFeb22_Proteinuria_Fig1.png\" alt=\"\" width=\"450\" height=\"253\" srcset=\"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2021\/12\/Schmid_TVPJanFeb22_Proteinuria_Fig1.png 962w, https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2021\/12\/Schmid_TVPJanFeb22_Proteinuria_Fig1-300x169.png 300w, https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2021\/12\/Schmid_TVPJanFeb22_Proteinuria_Fig1-768x432.png 768w\" sizes=\"(max-width: 450px) 100vw, 450px\" \/><\/a><p id=\"caption-attachment-24799\" class=\"wp-caption-text\">Figure 1. Severe abdominal distention and muscle wasting in a dog with a severe protein-losing nephropathy.<\/p><\/div>\n<p class=\"p1\"><span class=\"s1\">Even when concurrent hypoalbuminemia is not present, proteinuria affects the wellbeing of dogs and cats. Proteinuria in dogs is associated with an increased risk of uremic crisis, progressive worsening of azotemia, and death.<sup>2,3<\/sup> Similarly, proteinuria in cats with CKD has been shown to be a negative predictor of survival, with one study showing that a UPCR of greater than 0.4 is associated with a 4-fold increased risk of death or euthanasia compared with a UPCR of less than 0.2.<sup>4<\/sup> Furthermore, proteinuria may be associated with the development of azotemia in cats. One longitudinal study found that nonazotemic cats with a UPCR of greater than 0.2 were 3.5 times more likely to be azotemic 12\u00a0months later.<sup>5<\/sup><\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">In addition to promoting progression of kidney disease, persistent proteinuria has several extrarenal consequences, including sodium retention, edema, effusion, hypercholesterolemia, hypertension, hypercoagulability, muscle wasting, and weight loss.<sup>1,6,7<\/sup> Therefore, incidental proteinuria on routine diagnostic workups and geriatric screens should not be ignored.<span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<h2 class=\"p2\">The Normal Filtration Barrier<\/h2>\n<p class=\"p1\"><span class=\"s1\">Understanding the mechanisms of proteinuria requires a basic understanding of the normal glomerular filtration barrier. Blood comprises circulating proteins that are involved in hemostasis, fluid balance, and transportation. It takes a great deal of energy for the body to make proteins, and loss of these proteins would be wasteful. The glomerular filtration barrier exists to prevent their loss.<span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">The glomerulus is a tuft of capillaries that acts as an elegant sieve, allowing waste products to be filtered into the urine while preventing the loss of proteins and blood cells. The glomerulus forms a selective barrier that is best designed to keep albumin, the most abundant circulating protein, from leaking into the urine. As albumin is a 69 kDa negatively charged protein, it makes sense that the glomerular filtration barrier best excludes proteins larger than 65 kDa carrying a negative charge.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">Blood also contains proteins smaller than 65 kDa, such as retinol-binding protein, a transport protein for vitamin A. These low\u2013molecular weight proteins are freely filtered at the glomerulus but are reabsorbed by proximal tubular cells of the nephron, thereby preventing their loss. However, when there are increased amounts of low\u2013molecular weight proteins in the blood, the proximal tubular cells can become overwhelmed, resulting in proteinuria.<\/span><\/p>\n<h2 class=\"p2\">Classifying Proteinuria<\/h2>\n<p class=\"p1\"><span class=\"s1\">Proteinuria can be broadly classified as prerenal, renal, or postrenal. <\/span><strong><span class=\"s2\">BOX 1<\/span><\/strong><span class=\"s1\"> lists conditions that are associated with each type.<\/span><\/p>\n<div class=\"su-box su-box-style-default\" id=\"\" style=\"border-color:#003d45;border-radius:3px;\"><div class=\"su-box-title\" style=\"background-color:#007078;color:#ffffff;border-top-left-radius:1px;border-top-right-radius:1px\">BOX 1 Classification and Causes of Proteinuria <\/div><div class=\"su-box-content su-u-clearfix su-u-trim\" style=\"border-bottom-left-radius:1px;border-bottom-right-radius:1px\"><span class=\"s1\"><strong>Prerenal<\/strong> <\/span><\/p>\n<ul>\n<li class=\"p1\"><span class=\"s1\">Multiple myeloma (Bence Jones proteinuria) <\/span><\/li>\n<li class=\"p1\"><span class=\"s1\">Rhabdomyolysis (myoglobinuria) <\/span><\/li>\n<li class=\"p1\"><span class=\"s1\">Intravascular hemolysis (hemoglobinuria) <\/span><\/li>\n<li class=\"p1\"><span class=\"s1\">Drug reactions <\/span><\/li>\n<li class=\"p1\"><span class=\"s1\">Acute pancreatitis <\/span><\/li>\n<\/ul>\n<p class=\"p1\"><strong><span class=\"s1\">Renal <\/span><\/strong><\/p>\n<ul>\n<li class=\"p1\"><span class=\"s1\">F<\/span><span class=\"s1\">unctional <\/span>\n<ul>\n<li class=\"p1\"><span class=\"s1\">Stress, strenuous exercise, fever, heatstroke, congestive heart failure <\/span><\/li>\n<\/ul>\n<\/li>\n<li class=\"p1\"><span class=\"s1\">Pathologic <\/span>\n<ul>\n<li class=\"p1\"><span class=\"s1\">Tubular <\/span>\n<ul>\n<li class=\"p1\"><span class=\"s1\">Fanconi syndrome (basenjis, chlorambucil in cats) <\/span><\/li>\n<li class=\"p1\"><span class=\"s1\">Copper storage hepatopathy (Labrador retrievers) <\/span><\/li>\n<li class=\"p1\"><span class=\"s1\">Nephrotoxins (i.e., aminoglycosides) <\/span><\/li>\n<li class=\"p1\"><span class=\"s1\">Acute kidney injury <\/span><\/li>\n<li class=\"p1\"><span class=\"s1\">Chronic kidney disease <\/span><\/li>\n<li class=\"p1\"><span class=\"s1\">Leptospirosis <\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<li class=\"p1\"><span class=\"s1\">G<\/span><span class=\"s1\">lomerular <\/span>\n<ul>\n<li class=\"p1\"><span class=\"s1\">See <strong>BOX 2<\/strong> <\/span><\/li>\n<\/ul>\n<\/li>\n<li class=\"p1\"><span class=\"s1\">Interstitial <\/span>\n<ul>\n<li class=\"p1\"><span class=\"s1\">Interstitial nephritis (i.e., pyelonephritis) <\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"p1\"><span class=\"s1\"><strong>Postrenal<\/strong> <\/span><\/p>\n<ul>\n<li class=\"p1\"><span class=\"s1\">Urinary tract infection <\/span><\/li>\n<li class=\"p1\"><span class=\"s1\">Urolithiasis <\/span><\/li>\n<li class=\"p1\"><span class=\"s1\">Feline lower urinary tract disease <\/span><\/li>\n<li class=\"p1\"><span class=\"s1\">Transitional cell carcinoma<\/span><\/li>\n<li class=\"p1\"><span class=\"s1\">V<\/span><span class=\"s1\">aginitis\/prostatitis<\/span><\/li>\n<\/ul>\n<p><\/div><\/div>\n<h3 class=\"p3\">Prerenal Proteinuria<\/h3>\n<p class=\"p1\"><span class=\"s1\">Prerenal proteinuria occurs when normal proteins that are not normally present in plasma (i.e., hemoglobin or myoglobin) or abnormal proteins in the blood traverse normal glomerular capillary walls. For example, multiple myeloma results in the abnormal presence of immunoglobulin light chains in the plasma, leading to Bence Jones proteinuria. Prerenal causes of proteinuria can be excluded by evaluation of total protein to rule out dysproteinemia (the excessive synthesis of immunoglobulins).<sup>6<\/sup> The discovery of pigmenturia should prompt an investigation for hemoglobinemia and myoglobinemia.<span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<h3 class=\"p3\">Renal Proteinuria<\/h3>\n<p class=\"p1\"><span class=\"s1\">Renal proteinuria can be functional or pathological. <\/span>Functional renal proteinuria is secondary to altered renal<span class=\"s1\"> physiology caused by a transient phenomenon such as strenuous exercise, seizures, or fever.<sup>6-8<\/sup> Functional <\/span>proteinuria is characterized by transient, mild proteinuria<span class=\"s1\"> that resolves once the underlying condition resolves. Consequently, treatment is not indicated. Pathologic proteinuria, however, is secondary to pathologic changes to the kidney. As a result, the proteinuria is persistent and necessitates intervention. Pathologic renal proteinuria is further classified into glomerular, tubular, and interstitial proteinuria, depending on the location of protein loss into the urine.<sup>6-8<\/sup><\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">Glomerular proteinuria, caused by<b> <\/b>alterations in glomerular selectivity, can result in high\u2013molecular weight proteinuria. Patients with glomerular proteinuria often have a UPCR greater than 2. Immune-mediated glomerulonephritis, glomerulosclerosis, amyloidosis, podocytopathies, and hypertension-induced glomerulopathy can all cause this type of proteinuria, which can be associated with numerous diseases and conditions (<\/span><strong><span class=\"s2\">BOX 2<\/span><\/strong><span class=\"s1\">).<span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<div class=\"su-box su-box-style-default\" id=\"\" style=\"border-color:#003d45;border-radius:3px;\"><div class=\"su-box-title\" style=\"background-color:#007078;color:#ffffff;border-top-left-radius:1px;border-top-right-radius:1px\">BOX 2 Causes of Glomerular Proteinuria <\/div><div class=\"su-box-content su-u-clearfix su-u-trim\" style=\"border-bottom-left-radius:1px;border-bottom-right-radius:1px\"><strong><span class=\"s1\"><span class=\"Apple-converted-space\">Vascular <\/span><\/span><\/strong><\/p>\n<ul>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Hypertension <\/span><\/span><\/li>\n<\/ul>\n<p class=\"p1\"><strong><span class=\"s1\"><span class=\"Apple-converted-space\">Infectious <\/span><\/span><\/strong><\/p>\n<ul>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Heartworm disease <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Ehrlichiosis <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Lyme disease <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Leptospirosis <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Leishmaniasis <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">T<\/span><\/span><span class=\"s1\"><span class=\"Apple-converted-space\">rypanosomiasis <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Hepatozoonosis <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Babesiosis <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Anaplasmosis <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Feline immunodeficiency virus <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Feline infectious peritonitis <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Coccidiodomycosis <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Chronic pyoderma <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Bacterial endocarditis <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Schistosomiasis <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Bartonellosis <\/span><\/span><\/li>\n<\/ul>\n<p class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Immune-mediated<\/strong> <\/span><\/span><\/p>\n<ul>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Systemic lupus erythematosus <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Immune-mediated polyarthritis <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Inflammatory <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Pancreatitis <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Cholangiohepatitis <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Pyoderma <\/span><\/span><\/li>\n<\/ul>\n<p class=\"p1\"><strong><span class=\"s1\"><span class=\"Apple-converted-space\">Neoplastic <\/span><\/span><\/strong><\/p>\n<ul>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Lymphoma <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Leukemia <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Mast cell tumors <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Primary erythrocytosis <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Others <\/span><\/span><\/li>\n<\/ul>\n<p class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Endocrine\/metabolic<\/strong> <\/span><\/span><\/p>\n<ul>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Hyperadrenocorticism <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Hyperthyroidism <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Hyperlipidemia <\/span><\/span><\/li>\n<\/ul>\n<p class=\"p1\"><strong><span class=\"s1\"><span class=\"Apple-converted-space\">Drugs <\/span><\/span><\/strong><\/p>\n<ul>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Glucocorticoids <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Trimethoprim-sulfamethoxazole drugs <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\">Tyrosine kinase inhibitors (masitinib, toceranib) <\/span><\/span><\/li>\n<\/ul>\n<p class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Breed-related<\/strong> <\/span><\/span><\/p>\n<ul>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Renal dysplasia:<\/strong> Alaskan malamute, beagle, Chow Chow, golden retriever, Lhasa apso, miniature schnauzer, Shih Tzu, standard poodle <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Amyloidosis:<\/strong> Chinese Shar-Pei, beagle, English foxhound, English bulldog, Abyssinian and Siamese cats <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Membranous nephropathy:<\/strong> Doberman pinscher <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Membranoproliferative glomerulonephritis:<\/strong> Bernese mountain dog <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Immune-complex glomerulonephritis:<\/strong> Brittany spaniel, basenji <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Type II collagen defect:<\/strong> Newfoundland <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Type IV collagen defect:<\/strong> Bull terrier, English cocker spaniel, English springer spaniel, Samoyed<\/span><\/span><\/li>\n<\/ul>\n<p><\/div><\/div>\n<p class=\"p1\"><span class=\"s1\">Tubular proteinuria<b> <\/b>is caused by<b> <\/b>impaired tubular recovery of low\u2013molecular weight plasma proteins that normally traverse glomerular capillaries. These patients often have a UPCR less than 2. Causes include Fanconi syndrome and nephrotoxins.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">Interstitial proteinuria<b> <\/b>is caused by<b> <\/b>inflammatory lesions that result in leakage of proteins into the urine from peritubular capillaries (e.g., pyelonephritis). The degree of proteinuria varies and can be marked.<\/span><\/p>\n<h3 class=\"p3\">Postrenal Proteinuria<\/h3>\n<p class=\"p1\"><span class=\"s1\">Postrenal proteinuria results from entry of protein into the urine after urine enters the renal pelvis. Sources may be urinary (i.e., stones in the urinary collecting system, urinary tract infections, transitional cell carcinoma) or extraurinary (i.e., hemorrhagic or exudative processes affecting the genital tract). Postrenal causes can be excluded by collecting urine via cystocentesis, documenting a negative urine culture, and conducting imaging to rule out the presence of uroliths and neoplasia.<sup>6<\/sup><span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<h2 class=\"p2\">Detecting Proteinuria<\/h2>\n<h2 class=\"p3\">Urine Dipstick<\/h2>\n<p class=\"p1\"><span class=\"s1\">On routine urinalysis, proteinuria is initially identified using a urine dipstick, which semi-quantifies proteinuria as negative, trace, and 1+ to 4+ reactions. Traditional dipsticks generally detect urine albumin present at a concentration of greater than 30 mg\/dL. This test is based on the principle that negatively charged proteins such as albumin, for which the test is most sensitive, will cause a pH indicator dye to shift color from yellow to green to blue. Consequently, alkaline urine (pH &gt;7.5) may result in a color change even in the absence of proteinuria (false positive).<sup>9<\/sup> False-negative results may occur with Bence Jones proteinuria and dilute or acidic urine.<span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">The first step is to determine if the degree of proteinuria is significant in light of the urine specific gravity (USG). For example, 1+ proteinuria in a dog with a USG of 1.04 is unlikely to be significant, whereas a 1+ proteinuria with a USG of 1.008 is likely to be significant and warrants further investigation with a UPCR.<span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<h3 class=\"p3\">Sulfosalicylic Acid Test<\/h3>\n<p class=\"p1\"><span class=\"s1\">The sulfosalicylic acid (SSA) test is used by many laboratories to confirm proteinuria seen on a urine <\/span>dipstick. In addition to albumin, the SSA test can detect Bence Jones proteins and globulins. False-positive results <span class=\"s1\">can occur if the urine contains radiographic contrast agents, penicillins, or cephalosporins.<span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<h3 class=\"p3\">Microalbuminuria Tests<\/h3>\n<p class=\"p1\"><span class=\"s1\">Microalbuminuria tests can detect concentrations of albumin in the urine that are less than 1 mg\/dL. Transient microalbuminuria can be observed in a variety of conditions. Therefore, investigation is only indicated in patients with persistent microalbuminuria, defined as microalbuminuria found repeatedly in 3 or more urine specimens obtained 2 or more weeks apart that cannot be attributed to a postrenal cause.<sup>6<\/sup><\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">Urine testing for microalbuminuria should be considered for animals with chronic illness that might be complicated by proteinuric nephropathies and screening of dogs and cats at risk for hereditary nephropathy, to detect onset as early as possible.<\/span><\/p>\n<h3 class=\"p3\">Urine Protein:Creatinine Ratio<\/h3>\n<p class=\"p1\"><span class=\"s1\">Following detection of proteinuria on urinalysis, quantification using a UPCR may be indicated. The UPCR standardizes protein loss compared to creatinine. This adjusts the amount of protein loss for variations in USG and glomerular filtration rate. A UPCR from a spot urine sample accurately reflects the quantity of protein excreted in the urine over a 24-hour period. A result less than 0.2 is considered normal; a result of 0.2 to 0.5 in dogs and 0.2 to 0.4 in cats is consistent with borderline proteinuria.<sup>6<\/sup> Measuring a UPCR on a single urine sample, averaging UPCRs from 3 consecutive daily urine samples, and pooling 3\u00a0consecutive daily urine samples to measure a single UPCR all give similar results.<sup>10,11<\/sup> Therefore, there is no evidence that any individual method for monitoring the UPCR is superior.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">To determine if this measurement is indicated, the clinician must (1) document that the proteinuria is persistent and (2) rule out prerenal and postrenal causes. Persistent proteinuria is proteinuria documented on a minimum of 3 urinalyses 2 or more weeks apart. However, if the patient is presenting for a workup of hypoalbuminemia, a UPCR is indicated even if it is the first documentation of proteinuria on a urinalysis. As inflammatory conditions such as pancreatitis can result in transient proteinuria, it is recommended that a UPCR be performed once they have resolved.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">Proteinuria can result from urinary tract infections, urinary stones, and other causes of postrenal inflammation; therefore, a UPCR should not be performed in dogs with an active urine sediment or <\/span>urolithiasis. A negative urine culture should be obtained<span class=\"s1\"> prior to submitting a urine sample for a UPCR. Although hematuria can result in proteinuria, it should <\/span>not significantly affect the UPCR unless gross hematuria<span class=\"s1\"> is present. A UPCR is thought to be an accurate measure of proteinuria in cases with microscopic hematuria but grossly yellow to orange urine.<\/span><\/p>\n<h2 class=\"p2\">Proteinuria and Chronic Kidney Disease<\/h2>\n<p class=\"p1\"><span class=\"s1\">As previously mentioned, proteinuria is a negative prognostic indicator in dogs and cats with CKD.<sup>8<\/sup> Consequently, every dog and cat diagnosed with CKD should be substaged with a UPCR when there is no evidence of urinary tract inflammation or hemorrhage and dysproteinemias have been ruled out by measurement of plasma proteins. The International Renal Interest Society (<a href=\"http:\/\/www.iris-kidney.com\/\">IRIS<\/a>) substaging schematic is included in <\/span><span class=\"s2\">table 1<\/span><span class=\"s1\">. It is recommended that patients that are persistently borderline proteinuric be reevaluated within 2 months.<span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<h2 class=\"p2\">When to Intervene: What is Considered Too Much Protein?<\/h2>\n<p class=\"p1\"><span class=\"s1\">In a patient with normal kidney function, treatment is indicated when the UPCR is 2 or greater, as glomerular proteinuria is likely.<sup>6<\/sup> Diagnostic investigation for an underlying cause is recommended when the UPCR is 1\u00a0or greater or there is persistent and progressive microalbuminuria. A UPCR greater than 0.5 in a dog and 0.4 in a cat necessitates monitoring so the proper intervention can be taken should the UPCR progress.<sup>6<\/sup><\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">For animals with CKD, it is recommended that a UPCR greater than 0.5 in dogs or 0.4 in cats be investigated and treated. More information can be found on the <a href=\"http:\/\/www.iris-kidney.com\/\">IRIS website<\/a>.<span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<h2 class=\"p2\">Diagnostic Approach to Proteinuria<\/h2>\n<p class=\"p1\"><span class=\"s1\">In general, the diagnostic approach to proteinuria begins with collection of a comprehensive history, including signalment, environmental exposures, and a thorough travel history. Many dog breeds have predispositions for <\/span>glomerular disease, which should be considered (<strong><span class=\"s3\">BOX 2<\/span><\/strong>).<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">On physical examination, it is important to evaluate blood pressure along with a fundic examination. Next, a minimum database allows screening for concurrent evidence of diseases that may result in proteinuria. Azotemia is a reflection of the number of functional nephrons, whereas glomerular proteinuria results from a defect in the glomerular selectivity, independent of the number of functional nephrons. Therefore, patients with proteinuria may or may not be azotemic and azotemic animals may or may not have proteinuria.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">Testing for infectious diseases associated with glomerular proteinuria (<\/span><strong><span class=\"s2\">BOX 2<\/span><\/strong><span class=\"s1\">) should be based on each patient\u2019s travel history and risk. For example, it is recommended that a dog living in a Lyme-endemic area be tested for antibodies against <a href=\"https:\/\/todaysveterinarypractice.com\/lyme-disease\/\">Lyme<\/a> and other <a href=\"https:\/\/todaysveterinarypractice.com\/tick-borne-rickettsial-infections-of-dogs\/\">rickettsial<\/a> diseases carried by the same tick vector (<i>Ixodes <\/i>species), such as <i>Anaplasma phagocytophilum. <\/i>Empiric treatment with doxycycline (5 mg\/kg PO q12h) may be initiated while awaiting the results of vector-borne disease testing and, if well tolerated, continued for 4\u00a0weeks. In addition, tetracyclines such as doxycycline may have an anti-inflammatory effect on the glomerular basement membrane through the inhibition of matrix metallopeptidases, a family of extracellular proteinases that promote remodeling of the glomerulus.<sup>12<\/sup><span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">This diagnostic approach is typically sufficient for a dog or cat with incidental mild to moderate proteinuria. However, for a patient with a high level of proteinuria (UPCR &gt;3.5), progressive proteinuria despite treatment, hypertension, hypoalbuminemia, and\/or azotemia, additional diagnostics are indicated. Diagnostic imaging, including abdominal ultrasonography and thoracic radiography, should be performed. Patients with hypertension should be investigated for endocrine diseases (e.g., hyperadrenocorticism, pheochromocytoma, hyperaldosteronism), as idiopathic hypertension is relatively uncommon in dogs and cats.<sup>13<\/sup> Documentation of hypoalbuminemia warrants investigation for liver dysfunction and gastrointestinal losses with bile acids and testing for malabsorptive gastrointestinal diseases (e.g., serum cobalamin and folate, fecal flotation), respectively.<span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<h2 class=\"p2\">Therapeutic Approach to Proteinuria<\/h2>\n<p class=\"p1\"><span class=\"s1\">The therapeutic approach to proteinuria can be broken down into 5 components: inhibition of the renin-angiotensin-aldosterone system, identification and treatment of systemic hypertension, nutritional considerations, anticoagulant therapy, and immunosuppression. An algorithm for the therapeutic approach to proteinuria in non-CKD patients is provided in <strong>F<span class=\"s2\">IGURE<\/span><\/strong><\/span><strong><span class=\"s2\">\u00a02<\/span><\/strong><span class=\"s1\">.<span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<p class=\"p1\"><a href=\"https:\/\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2021\/12\/TVP-2022-0102_Proteinuria.png\"><img decoding=\"async\" class=\"aligncenter size-full wp-image-31227\" src=\"https:\/\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2021\/12\/TVP-2022-0102_Proteinuria.png\" alt=\"\" width=\"2560\" height=\"1577\" srcset=\"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2021\/12\/TVP-2022-0102_Proteinuria.png 2560w, https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2021\/12\/TVP-2022-0102_Proteinuria-300x185.png 300w, https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2021\/12\/TVP-2022-0102_Proteinuria-1024x631.png 1024w, https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2021\/12\/TVP-2022-0102_Proteinuria-768x473.png 768w, https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2021\/12\/TVP-2022-0102_Proteinuria-1536x946.png 1536w, https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2021\/12\/TVP-2022-0102_Proteinuria-2048x1262.png 2048w\" sizes=\"(max-width: 2560px) 100vw, 2560px\" \/><\/a><\/p>\n<h3 class=\"p3\">Inhibition of the Renin-Angiotensin-Aldosterone System<\/h3>\n<p class=\"p1\"><span class=\"s1\">The mainstay of treatment for proteinuria is inhibition of the renin-angiotensin-aldosterone system (RAAS). The goal is to lessen glomerular capillary pressure by altering the hemodynamic forces that promote transglomerular movement of proteins. In veterinary medicine, the main RAAS inhibitors used are angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs; <\/span><strong><span class=\"s2\">BOX 3<\/span><\/strong><span class=\"s1\">).<span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<div class=\"su-box su-box-style-default\" id=\"\" style=\"border-color:#003d45;border-radius:3px;\"><div class=\"su-box-title\" style=\"background-color:#007078;color:#ffffff;border-top-left-radius:1px;border-top-right-radius:1px\">BOX 3 Renin-Angiotensin-Aldosterone System (RAAS) Inhibition and Treatment of Hypertension <\/div><div class=\"su-box-content su-u-clearfix su-u-trim\" style=\"border-bottom-left-radius:1px;border-bottom-right-radius:1px\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Angiotensin-converting enzyme inhibitors (both indications)<\/strong> <\/span><\/span><\/p>\n<ul>\n<li class=\"p1\"><strong><span class=\"s1\"><span class=\"Apple-converted-space\">Enalapril <\/span><\/span><\/strong>\n<ul>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Initial dose:<\/strong> 0.25\u20130.5 mg\/kg PO q12\u201324h<sup>14,15<\/sup> (azotemic animals should start at 0.25 mg\/kg q24h and then escalate to q12h; most dogs will need q12h dosing<sup>15,16<\/sup>) <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Dose escalations:<\/strong> 0.5 mg\/kg\/day <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Maximum dose:<\/strong> 2 mg\/kg\/day <\/span><\/span><\/li>\n<\/ul>\n<\/li>\n<li class=\"p1\"><strong><span class=\"s1\"><span class=\"Apple-converted-space\">Benazepril <\/span><\/span><\/strong>\n<ul>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Initial dose:<\/strong> 0.5 mg\/kg PO q24h or divided to 0.25 mg\/kg PO q12h<sup>14,15,17<\/sup> <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Dose escalation:<\/strong> Increase to q12h dosing, then consider increasing dose by 0.5 mg\/kg\/day <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Maximum dose:<\/strong> 2 mg\/kg\/day <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Note:<\/strong> Benazepril is also eliminated via hepatic routes and therefore does not need to be dose reduced in azotemic patients. <\/span><\/span><\/li>\n<\/ul>\n<\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Side effects:<\/strong> Gastrointestinal upset (anorexia, vomiting, diarrhea), weakness, hypotension, hyperkalemia <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Monitoring:<\/strong> Creatinine (goal &lt;30% increase),15 potassium, and blood pressure 5\u20137 days after initiation of treatment and each dose change <\/span><\/span><\/li>\n<\/ul>\n<p><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Angiotensin receptor blockers (RAAS inhibition)<\/strong> <\/span><\/span><\/p>\n<ul>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Telmisartan:<\/strong> 0.5\u20131 mg\/kg PO q24h up to 2\u00a0mg\/kg\/day<sup>14,15,17,18<\/sup> <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Losartan:<\/strong> 0.125\u20130.5 mg\/kg PO q24h up to 1 mg\/kg\/day<sup>14,15,17<\/sup> (azotemic animals should start at 0.125 mg\/kg q24h and not exceed 0.25\u00a0mg\/kg\/day) <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Side effects:<\/strong> Gastrointestinal upset (anorexia, vomiting, diarrhea), weakness, hypotension, hyperkalemia <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Monitoring:<\/strong> Creatinine (goal &lt;30% increase),15 potassium, and blood pressure 5\u20137 days after initiation of treatment and each dose change <\/span><\/span><\/li>\n<\/ul>\n<p class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Calcium channel blockers (hypertension)<\/strong> <\/span><\/span><\/p>\n<ul>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Amlodipine<\/strong> <\/span><\/span>\n<ul>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Dogs:<\/strong> 0.1 mg\/kg PO q24h titrated up to effect without exceeding 0.5 mg\/kg PO q24h<sup>14,17<\/sup> <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Cats:<\/strong> 0.625-1.25 mg\/cat PO q24h titrated to effect<sup>14,17<\/sup> <\/span><\/span><\/li>\n<\/ul>\n<\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Side effects:<\/strong> Gingival hyperplasia, hypotension <\/span><\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><span class=\"Apple-converted-space\"><strong>Monitoring:<\/strong> Blood pressure 5\u201310 days after initiation of treatment and each dose change<\/span><\/span><\/li>\n<\/ul>\n<p><\/div><\/div>\n<p class=\"p1\"><span class=\"s1\">ACEIs, such as enalapril and benazepril, are the RAAS inhibitors most commonly prescribed to treat systemic hypertension and proteinuria in dogs and cats. They function by decreasing serum concentrations of angiotensin II and aldosterone, thereby reducing glomerular transcapillary hydrostatic pressure and systemic blood pressure.<sup>19,20<\/sup> ACEIs have been shown to reduce proteinuria in dogs.<sup>16<\/sup><\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">ARBs, such as telmisartan and losartan, have been used in veterinary medicine to treat systemic hypertension and, more recently, proteinuria. ARBs selectively inhibit angiotensin II subtype 1 receptors, which mediate the adverse effects of angiotensin II on the cardiovascular system and kidneys. When compared with enalapril, telmisartan has been shown to result in a greater proportion of dogs reaching a goal UPCR reduction of 50% or more of baseline after 30 days of treatment.<sup>21<\/sup> A recent retrospective study in dogs on telmisartan alone or in conjunction with benazepril or mycophenolate confirmed that telmisartan is effective in reducing proteinuria compared with baseline and is well tolerated.<sup>18<\/sup> In cats with CKD, telmisartan has been shown to be at least as effective as benazepril in reducing proteinuria and significantly reduced UPCRs from baseline at all time points.<sup>22<\/sup><\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">While decreasing glomerular transcapillary hydrostatic pressure, ACEIs and ARBs also reduce glomerular filtration rate. Consequently, it is prudent to initiate therapy at a lower dosage in azotemic patients and recheck serum creatinine concentrations within 5 to 7\u00a0days. In addition, both medications reduce serum aldosterone, which may result in hyperkalemia.<\/span><\/p>\n<h3 class=\"p3\">Identification and Treatment of Systemic Hypertension<\/h3>\n<p class=\"p1\"><span class=\"s1\">All patients with proteinuria warrant blood pressure evaluation, as hypertension can contribute to proteinuria and lead to target organ damage.<sup>3,13<\/sup> Given the relatively common prevalence of anxiety-induced, or \u201cwhite coat,\u201d hypertension, and the knowledge that hypertension requires lifelong therapy, it is important to be absolutely certain about the diagnosis. In general, documentation of a systolic blood pressure greater than 160 mm Hg on 2 or more occasions provides a diagnosis of systemic hypertension and indicates the need for antihypertensive therapy (<\/span><strong><span class=\"s2\">BOX 3<\/span><\/strong><span class=\"s1\">). However, the presence of target organ damage such as retinopathy justifies initiation of treatment after a single measurement.<sup>13<\/sup><\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">Because of their antiproteinuric effect, RAAS inhibitors are often selected as first-line hypertensive agents in dogs. RAAS inhibitors typically reduce systolic blood pressure by only 10 to 15 mm Hg. Consequently, severely hypertensive dogs (systolic blood pressure &gt;200\u00a0mm Hg) often require concurrent treatment with a calcium channel blocker (CCB) such as amlodipine.<sup>13<\/sup> Using CCBs alone in dogs should be avoided as they preferentially dilate the renal afferent arteriole, exposing the glomerulus to increases in glomerular capillary hydrostatic pressure, which will worsen proteinuria.<sup>23<\/sup><\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">In cats, ACEIs alone are unlikely to result in resolution of hypertension.<sup>13<\/sup> Consequently, the CCB amlodipine is considered the first line of treatment for hypertension in cats. A mean decrease of 28 to 55 mm Hg in systolic blood pressure is typically seen with amlodipine.<sup>24,25<\/sup> The ARB telmisartan has been shown to significantly decrease mean systolic blood pressure in cats with blood pressures up to 200 mm Hg.<sup>26<\/sup><\/span><\/p>\n<h3 class=\"p3\">Nutritional Considerations for Proteinuria<\/h3>\n<p class=\"p1\"><span class=\"s1\">A protein-restricted diet (35 to 40 g\/1000 kcal in dogs, 65 to 70 g\/1000 kcal in cats) with moderate amounts of high-quality protein has been recommended for patients with proteinuria.<sup>27<\/sup> The generally accepted benefits of moderate protein restriction are to reduce the generation of uremic toxins, intraglomerular pressure, and magnitude of proteinuria.<sup>6,15<\/sup> However, too-early introduction of a protein-restricted diet may lead to protein malnutrition and loss of lean body mass. The timing and degree of protein restriction for both dogs and cats remain a point of controversy.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">In dogs with experimentally induced CKD, supplementation of omega-3 fatty acids has been shown to decrease proteinuria, lower glomerular pressure, and decrease the production of proinflammatory eicosanoids.<sup>15,28<\/sup> Patients can be supplemented with omega-3 fatty acids at roughly 300 mg of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) <\/span>combined per 10 lb or dosed using previously published<span class=\"s1\"> recommendations (140 \u00d7 [weight in kg]<sup>0.75<\/sup> mg DHA and EPA combined).<sup>29<\/sup> The total daily dose should be divided with meals. It is recommended to start at 25% to 50% of the daily dose and slowly work up to lessen the occurrence of side effects such as diarrhea.<span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<h3 class=\"p3\">Anticoagulant Therapy<\/h3>\n<p class=\"p1\"><span class=\"s1\">Thromboembolism is a well-recognized complication of proteinuria in dogs and people, with the prevalence of thromboembolism in dogs with proteinuric kidney disease being reported as high as 25%.<sup>1<\/sup> In addition, a recent study reported the concurrent presence of a PLN in 32 of 100 dogs with aortic thrombosis.<sup>30<\/sup><span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">The mechanism of thromboembolism formation in dogs with proteinuria has not been well established. Historically, it was thought that the loss of antithrombin III, which is similar in size to albumin, was the main contributor. However, it has been shown that 96% of proteinuric dogs, defined as dogs with a UPCR greater than 2, have 1 or more parameter on thromboelastography suggestive of hypercoagulability independent of antithrombin III activity.<sup>31<\/sup><\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">To date, there is no evidence regarding the efficacy of antithrombotic agents in venous thromboembolism prophylaxis. In cats, clopidogrel has been shown to be more effective than aspirin in reducing the likelihood of cardiogenic arterial thromboembolism.<sup>32<\/sup> Consequently, clopidogrel is the treatment of choice for cats with PLN (<\/span><strong><span class=\"s2\">BOX 4<\/span><\/strong><span class=\"s1\">). In dogs, treatment with aspirin or clopidogrel is currently recommended.<sup>15<\/sup> In a recent study of dogs with PLN receiving clopidogrel (1.8 to 3.2 mg\/kg\/day) or aspirin (1 to 1.2 mg\/kg\/day), no dogs receiving aspirin had documentation of platelet inhibition at any time point, whereas platelet function testing in most dogs receiving clopidogrel showed platelet inhibition.<sup>34<\/sup> However, it is important to note that the aspirin dose in this study may have been too low to see consistent platelet inhibition. A previous study reported that only one-third of healthy dogs receiving a low dose of aspirin (1 mg\/kg\/day) had consistent platelet inhibition, whereas those receiving a slightly higher dose of aspirin (2 mg\/kg\/day) had consistent platelet inhibition.<sup>33<\/sup> As a result, a dose of at least 2 mg\/kg\/day of aspirin is currently recommended.<\/span><\/p>\n<div class=\"su-box su-box-style-default\" id=\"\" style=\"border-color:#003d45;border-radius:3px;\"><div class=\"su-box-title\" style=\"background-color:#007078;color:#ffffff;border-top-left-radius:1px;border-top-right-radius:1px\">BOX 4 Anticoagulant Therapy<\/div><div class=\"su-box-content su-u-clearfix su-u-trim\" style=\"border-bottom-left-radius:1px;border-bottom-right-radius:1px\"><strong><span class=\"s1\">Aspirin <\/span><\/strong><\/p>\n<ul>\n<li class=\"p1\"><span class=\"s1\"><strong>Mechanism:<\/strong> Cyclooxygenase-1 inhibitor, reduction of prostaglandin and thromboxane synthesis; irreversible inhibition of platelet function <\/span><\/li>\n<li class=\"p1\"><strong><span class=\"s1\">Dose: <\/span><\/strong>\n<ul>\n<li class=\"p1\"><span class=\"s1\"><strong>Dogs:<\/strong> 2\u20135 mg\/kg PO q24h<sup>14,17,33<\/sup> <\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><strong>Cats:<\/strong> Clopidogrel appears to be safer and more effective in cats<sup>32<\/sup> <\/span><\/li>\n<\/ul>\n<\/li>\n<li class=\"p1\"><span class=\"s1\"><strong>Side effects:<\/strong> Gastrointestinal upset (nausea, anorexia, vomiting, diarrhea), occult gastrointestinal blood loss <\/span><\/li>\n<\/ul>\n<p><span class=\"s1\"><strong>Clopidogrel<\/strong> <\/span><\/p>\n<ul>\n<li class=\"p1\"><span class=\"s1\"><strong>Mechanism:<\/strong> Adenosine diphosphate receptor inhibitor; irreversible inhibition of platelet function <\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><strong>Dose:<\/strong> <\/span>\n<ul>\n<li class=\"p1\"><span class=\"s1\"><strong>Dogs:<\/strong> 2\u20133 mg\/kg PO q24h<sup>14,17<\/sup> <\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><strong>Cats:<\/strong> 18.75 mg\/cat PO q24h<sup>14,17<\/sup> <\/span><\/li>\n<\/ul>\n<\/li>\n<li class=\"p1\"><span class=\"s1\"><strong>Side effects:<\/strong> Well tolerated; may cause gastrointestinal upset (vomiting, anorexia, diarrhea)<\/span><\/li>\n<\/ul>\n<p><\/div><\/div>\n<p class=\"p1\"><span class=\"s1\">In people with nephrotic syndrome, a severe form of PLN, low\u2013molecular weight heparin and oral warfarin are the most often prescribed prophylactic anticoagulants.<sup>35<\/sup> These medications are not routinely used in veterinary medicine due to concerns surrounding administration, monitoring, and potential complications. In addition, heparin exerts its anticoagulant effects by potentiating antithrombin III, which is thought to be lost in the urine in dogs with glomerular disease. Factor Xa inhibitors such as rivaroxaban have not been studied in dogs with glomerular disease.<span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">In conclusion, clopidogrel (or aspirin in dogs only) is the treatment of choice for thromboprophylaxis in dogs and cats with glomerular proteinuria.<span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<h3 class=\"p3\">Immunosuppression<span class=\"Apple-converted-space\">\u00a0<\/span><\/h3>\n<p class=\"p1\"><span class=\"s1\">Immunosuppression is indicated when a kidney biopsy confirms immune-complex glomerulonephritis (ICGN). However, many dogs with glomerular disease are not biopsied owing to patient stability, availability, owner preferences, and\/or financial limitations. Extrapolating from a study of 501 kidney biopsies from dogs with suspected glomerular disease, it is estimated that approximately 50% of dogs with glomerular proteinuria have ICGN.<sup>36<\/sup> Considering the relatively high prevalence of ICGN, immunosuppression may be considered in patients that fail the standard therapies listed above.<span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<p class=\"p4\"><span class=\"s1\">In addition to failing standard medical therapy, all of the following criteria should be met before instituting immunosuppressive therapy:<sup>37<\/sup><span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<ul>\n<li class=\"p5\">Proteinuria is confirmed to be glomerular in origin (UPCR &gt;2).<\/li>\n<li class=\"p5\">Immunosuppression is not contraindicated (requires a full diagnostic workup to rule out infectious causes, including vector-borne diseases and pyelonephritis).<\/li>\n<li class=\"p5\">Signalment is not suggestive of a familial nephropathy or amyloidosis.<\/li>\n<li class=\"p5\">Serum creatinine is greater than 3 mg\/kg or progressive, or serum albumin is less than 2 g\/dL.<\/li>\n<\/ul>\n<p class=\"p1\"><span class=\"s1\">To date, there are limited data on immunosuppressive therapy in dogs with ICGN. The immunosuppressant of choice for rapidly progressive glomerular disease is mycophenolate (<\/span><strong><span class=\"s2\">BOX 5<\/span><\/strong><span class=\"s1\">). Alternative protocols include cyclosporine, cyclophosphamide, or chlorambucil with or without azathioprine on alternating days.<sup>37<\/sup><\/span><\/p>\n<div class=\"su-box su-box-style-default\" id=\"\" style=\"border-color:#003d45;border-radius:3px;\"><div class=\"su-box-title\" style=\"background-color:#007078;color:#ffffff;border-top-left-radius:1px;border-top-right-radius:1px\">BOX 5 Immunosuppressive Therapy<\/div><div class=\"su-box-content su-u-clearfix su-u-trim\" style=\"border-bottom-left-radius:1px;border-bottom-right-radius:1px\"><strong><span class=\"s1\">Mycophenolate <\/span><\/strong><\/p>\n<ul>\n<li class=\"p1\"><span class=\"s1\"><strong>Mechanism:<\/strong> Antagonizes purine metabolism <\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><strong>Dose:<\/strong> 10 mg\/kg PO q12h14,17,37 (renally excreted; azotemic animals should start at q24h) <\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><strong>Side effects:<\/strong> Gastrointestinal upset (vomiting, diarrhea); can be severe <\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><strong>Therapeutic drug monitoring:<\/strong> None indicated <\/span><\/li>\n<\/ul>\n<p class=\"p1\"><strong><span class=\"s1\">Cyclosporine <\/span><\/strong><\/p>\n<ul>\n<li class=\"p1\"><span class=\"s1\"><strong>Mechanism:<\/strong> Calcineurin inhibitor <\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><strong>Dose:<\/strong> 5 mg\/kg PO q12h increased to effect17,37 <\/span><\/li>\n<li class=\"p1\"><strong><span class=\"s1\">S<\/span><\/strong><span class=\"s1\"><strong>ide effects:<\/strong> Gastrointestinal upset (vomiting, diarrhea, anorexia), gingival hyperplasia <\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><strong>Therapeutic drug monitoring:<\/strong> Peak (2 hours post-dosing) levels in patients dosed q12h* <\/span>\n<ul>\n<li class=\"p1\"><strong><span class=\"s1\">P<\/span><\/strong><span class=\"s1\"><strong>harmacodynamic (preferred):<\/strong> T-cell interleukin-2 synthesis monitoring <\/span><\/li>\n<li class=\"p1\"><span class=\"s1\"><strong>Pharmacokinetic:<\/strong> Blood levels <\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"p1\"><span class=\"s1\">*Patients dosed q24h require a trough level taken just prior to their next dose in addition to a peak level.<\/span><\/p>\n<p><\/div><\/div>\n<p class=\"p1\"><span class=\"s1\">Owing to the adverse effects glucocorticoids can have on the kidneys and glomerulus, they are generally avoided for long-term management of ICGM. In fulminant cases when immediate immunosuppression is required, such as glomerulonephritis associated with systemic lupus erythematosus, short-term administration of glucocorticoids may be justified.<sup>37<\/sup><span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">Immunosuppression is continued for a minimum of 8\u00a0to 12 weeks before concluding a failed trial.<sup>37<\/sup> Patients on immunosuppressive therapy should be closely monitored for progression of glomerular disease and side effects of immunosuppression. If life-threatening infections or clinically intolerable side effects are encountered, immunosuppression should be discontinued. When a response is noted, it is recommended that immunosuppressive therapy be continued a minimum of 12 to 16 weeks, although, anecdotally, longer courses of immunosuppression are often necessary.<sup>37<\/sup> The decision to taper is based on resolution of proteinuria and involves close monitoring of the UPCR.<span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<h2 class=\"p2\">Monitoring Proteinuria and Adjusting Medications<\/h2>\n<p class=\"p1\"><span class=\"s1\">After initiation of treatment, the UPCR should be reevaluated in 2 to 4 weeks. The goal is to reach a UPCR less than 0.5 in dogs and 0.4 in cats or a greater than 50% reduction in UPCR compared with baseline.<sup>15<\/sup> If neither of these parameters is met, the dose should be increased (when possible) and the UPCR rechecked 2 to 4 weeks later.<span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">If no response is noted to an ACEI or an ARB, addition of the other medication (i.e., ACEI or ARB) may be indicated. The author\u2019s experience is that concurrent administration of an ACEI and an ARB may result in hyperkalemia and\/or progressive azotemia. Therefore, it is recommended that the dose of ACEI or ARB be reduced to the low end of dosing prior to adding a second agent, then increased slowly as needed if no adverse effects are seen.<span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">Once patients with glomerular disease have been stabilized, UPCR; urinalysis; systemic arterial blood pressure; and serum albumin, creatinine, and potassium concentrations should be monitored at least quarterly.<span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<h2 class=\"p2\">Prognosis<\/h2>\n<p class=\"p1\"><span class=\"s1\">The prognosis for dogs and cats with proteinuria is variable and likely depends on the underlying disease present. One study evaluating protein-losing glomerular disease in dogs reported a median survival of 28 days, with most cases succumbing to chronic renal disease (69.5%) or thromboembolic complications (22.2%).<sup>38<\/sup> However, this study included cases with amyloidosis that were more likely to be azotemic at presentation. Despite the poor prognosis, there were individual dogs that survived more than 3\u00a0years.<sup>38<\/sup><span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">It is likely that prognosis varies with each specific type of glomerular disease. However, most studies to date fail to provide a definitive histologic diagnosis or are biased toward death by inclusion of dogs with kidney tissue collected postmortem. As more kidney biopsies are performed, additional prognostic information will likely become available. For example, a recent study by the <a href=\"https:\/\/vet.osu.edu\/vmc\/international-veterinary-renal-pathology-service-ivrps\">International Veterinary Renal Pathology Service<\/a> found that dogs with focal segmental glomerulosclerosis, the most common non\u2013immune complex glomerular disease in dogs, had a median survival time of 258 days after biopsy.<sup>39<\/sup> More studies are needed to characterize the prognosis for various types of glomerular disease in dogs and cats. It is likely that earlier detection and treatment of proteinuria will lead to better outcomes.<span class=\"Apple-converted-space\">\u00a0<\/span><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In addition to promoting progression of kidney disease, persistent proteinuria has several extrarenal consequences, therefore incidental proteinuria on routine diagnostic workups and geriatric screens should not be ignored.<\/p>\n","protected":false},"author":9,"featured_media":24801,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"iawp_total_views":35241,"footnotes":""},"categories":[319],"tags":[13],"class_list":["post-24842","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-january-february-2022","tag-peer-reviewed","column-features","clinical_topics-urology-renal-medicine"],"acf":{"hide_sidebar":false,"hide_sidebar_ad":false,"hide_all_ads":false},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.7 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>A Clinical Approach to Proteinuria | Today&#039;s Veterinary Practice<\/title>\n<meta name=\"description\" content=\"In addition to promoting progression of kidney disease, persistent proteinuria has several extrarenal consequences, therefore incidental proteinuria on routine diagnostic workups and geriatric screens should not be ignored.\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"When Urine Trouble: A Clinical Approach to Proteinuria\" \/>\n<meta property=\"og:description\" content=\"In addition to promoting progression of kidney disease, persistent proteinuria has several extrarenal consequences, therefore incidental proteinuria on routine diagnostic workups and geriatric screens should not be ignored.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/urology-renal-medicine\/clinical-approach-to-proteinuria\/\" \/>\n<meta property=\"og:site_name\" content=\"Today&#039;s Veterinary Practice\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/todaysveterinarypractice\" \/>\n<meta property=\"article:published_time\" content=\"2021-12-14T14:26:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-06T13:03:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2021\/12\/Schmid_TVPJanFeb22_Proteinuria_MainImage.png\" \/>\n\t<meta property=\"og:image:width\" content=\"990\" \/>\n\t<meta property=\"og:image:height\" content=\"419\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandy Walsh, RVT, CVPM\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandy Walsh, RVT, CVPM\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"26 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/urology-renal-medicine\\\/clinical-approach-to-proteinuria\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/urology-renal-medicine\\\/clinical-approach-to-proteinuria\\\/\"},\"author\":{\"name\":\"Sandy Walsh, RVT, CVPM\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/#\\\/schema\\\/person\\\/a23b723e80e334bfb601dfa22ef8e6cd\"},\"headline\":\"When Urine Trouble: A Clinical Approach to Proteinuria\",\"datePublished\":\"2021-12-14T14:26:07+00:00\",\"dateModified\":\"2025-10-06T13:03:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/urology-renal-medicine\\\/clinical-approach-to-proteinuria\\\/\"},\"wordCount\":4564,\"publisher\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/urology-renal-medicine\\\/clinical-approach-to-proteinuria\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2021\\\/12\\\/Schmid_TVPJanFeb22_Proteinuria_MainImage.png\",\"keywords\":[\"Peer Reviewed\"],\"articleSection\":[\"January\\\/February 2022\"],\"inLanguage\":\"en-US\"},{\"@type\":[\"WebPage\",\"MedicalWebPage\"],\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/urology-renal-medicine\\\/clinical-approach-to-proteinuria\\\/\",\"url\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/urology-renal-medicine\\\/clinical-approach-to-proteinuria\\\/\",\"name\":\"A Clinical Approach to Proteinuria | Today&#039;s Veterinary Practice\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/urology-renal-medicine\\\/clinical-approach-to-proteinuria\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/urology-renal-medicine\\\/clinical-approach-to-proteinuria\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2021\\\/12\\\/Schmid_TVPJanFeb22_Proteinuria_MainImage.png\",\"datePublished\":\"2021-12-14T14:26:07+00:00\",\"dateModified\":\"2025-10-06T13:03:04+00:00\",\"description\":\"In addition to promoting progression of kidney disease, persistent proteinuria has several extrarenal consequences, therefore incidental proteinuria on routine diagnostic workups and geriatric screens should not be ignored.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/urology-renal-medicine\\\/clinical-approach-to-proteinuria\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/urology-renal-medicine\\\/clinical-approach-to-proteinuria\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/urology-renal-medicine\\\/clinical-approach-to-proteinuria\\\/#primaryimage\",\"url\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2021\\\/12\\\/Schmid_TVPJanFeb22_Proteinuria_MainImage.png\",\"contentUrl\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2021\\\/12\\\/Schmid_TVPJanFeb22_Proteinuria_MainImage.png\",\"width\":990,\"height\":419,\"caption\":\"Lothar Drechsel\\\/shutterstock.com\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/urology-renal-medicine\\\/clinical-approach-to-proteinuria\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"When Urine Trouble: A Clinical Approach to Proteinuria\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/#website\",\"url\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/\",\"name\":\"Today's Veterinary Practice\",\"description\":\"Peer-Reviewed Veterinary Journal\",\"publisher\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/#organization\",\"name\":\"Today's Veterinary Practice\",\"url\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/todaysveterinarypractice.com\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2022\\\/01\\\/tvp-logo.png\",\"contentUrl\":\"https:\\\/\\\/todaysveterinarypractice.com\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2022\\\/01\\\/tvp-logo.png\",\"width\":179,\"height\":89,\"caption\":\"Today's Veterinary Practice\"},\"image\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/todaysveterinarypractice\",\"https:\\\/\\\/www.youtube.com\\\/thenavc\"],\"email\":\"info@navc.com\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/#\\\/schema\\\/person\\\/a23b723e80e334bfb601dfa22ef8e6cd\",\"name\":\"Sandy Walsh, RVT, CVPM\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b78c33d196d0e8e21eec7d2e93b220ee8c639838096e6657be89397cdbd2ee7e?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b78c33d196d0e8e21eec7d2e93b220ee8c639838096e6657be89397cdbd2ee7e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b78c33d196d0e8e21eec7d2e93b220ee8c639838096e6657be89397cdbd2ee7e?s=96&d=mm&r=g\",\"caption\":\"Sandy Walsh, RVT, CVPM\"},\"sameAs\":[\"http:\\\/\\\/tvb.com\"],\"url\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/author\\\/swalsh\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"A Clinical Approach to Proteinuria | Today&#039;s Veterinary Practice","description":"In addition to promoting progression of kidney disease, persistent proteinuria has several extrarenal consequences, therefore incidental proteinuria on routine diagnostic workups and geriatric screens should not be ignored.","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"When Urine Trouble: A Clinical Approach to Proteinuria","og_description":"In addition to promoting progression of kidney disease, persistent proteinuria has several extrarenal consequences, therefore incidental proteinuria on routine diagnostic workups and geriatric screens should not be ignored.","og_url":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/urology-renal-medicine\/clinical-approach-to-proteinuria\/","og_site_name":"Today&#039;s Veterinary Practice","article_publisher":"https:\/\/www.facebook.com\/todaysveterinarypractice","article_published_time":"2021-12-14T14:26:07+00:00","article_modified_time":"2025-10-06T13:03:04+00:00","og_image":[{"width":990,"height":419,"url":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2021\/12\/Schmid_TVPJanFeb22_Proteinuria_MainImage.png","type":"image\/png"}],"author":"Sandy Walsh, RVT, CVPM","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Sandy Walsh, RVT, CVPM","Est. reading time":"26 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/urology-renal-medicine\/clinical-approach-to-proteinuria\/#article","isPartOf":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/urology-renal-medicine\/clinical-approach-to-proteinuria\/"},"author":{"name":"Sandy Walsh, RVT, CVPM","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/#\/schema\/person\/a23b723e80e334bfb601dfa22ef8e6cd"},"headline":"When Urine Trouble: A Clinical Approach to Proteinuria","datePublished":"2021-12-14T14:26:07+00:00","dateModified":"2025-10-06T13:03:04+00:00","mainEntityOfPage":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/urology-renal-medicine\/clinical-approach-to-proteinuria\/"},"wordCount":4564,"publisher":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/#organization"},"image":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/urology-renal-medicine\/clinical-approach-to-proteinuria\/#primaryimage"},"thumbnailUrl":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2021\/12\/Schmid_TVPJanFeb22_Proteinuria_MainImage.png","keywords":["Peer Reviewed"],"articleSection":["January\/February 2022"],"inLanguage":"en-US"},{"@type":["WebPage","MedicalWebPage"],"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/urology-renal-medicine\/clinical-approach-to-proteinuria\/","url":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/urology-renal-medicine\/clinical-approach-to-proteinuria\/","name":"A Clinical Approach to Proteinuria | Today&#039;s Veterinary Practice","isPartOf":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/urology-renal-medicine\/clinical-approach-to-proteinuria\/#primaryimage"},"image":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/urology-renal-medicine\/clinical-approach-to-proteinuria\/#primaryimage"},"thumbnailUrl":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2021\/12\/Schmid_TVPJanFeb22_Proteinuria_MainImage.png","datePublished":"2021-12-14T14:26:07+00:00","dateModified":"2025-10-06T13:03:04+00:00","description":"In addition to promoting progression of kidney disease, persistent proteinuria has several extrarenal consequences, therefore incidental proteinuria on routine diagnostic workups and geriatric screens should not be ignored.","breadcrumb":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/urology-renal-medicine\/clinical-approach-to-proteinuria\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/urology-renal-medicine\/clinical-approach-to-proteinuria\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/urology-renal-medicine\/clinical-approach-to-proteinuria\/#primaryimage","url":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2021\/12\/Schmid_TVPJanFeb22_Proteinuria_MainImage.png","contentUrl":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2021\/12\/Schmid_TVPJanFeb22_Proteinuria_MainImage.png","width":990,"height":419,"caption":"Lothar Drechsel\/shutterstock.com"},{"@type":"BreadcrumbList","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/urology-renal-medicine\/clinical-approach-to-proteinuria\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/"},{"@type":"ListItem","position":2,"name":"When Urine Trouble: A Clinical Approach to Proteinuria"}]},{"@type":"WebSite","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/#website","url":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/","name":"Today's Veterinary Practice","description":"Peer-Reviewed Veterinary Journal","publisher":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/#organization","name":"Today's Veterinary Practice","url":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/#\/schema\/logo\/image\/","url":"https:\/\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2022\/01\/tvp-logo.png","contentUrl":"https:\/\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2022\/01\/tvp-logo.png","width":179,"height":89,"caption":"Today's Veterinary Practice"},"image":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/todaysveterinarypractice","https:\/\/www.youtube.com\/thenavc"],"email":"info@navc.com"},{"@type":"Person","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/#\/schema\/person\/a23b723e80e334bfb601dfa22ef8e6cd","name":"Sandy Walsh, RVT, CVPM","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b78c33d196d0e8e21eec7d2e93b220ee8c639838096e6657be89397cdbd2ee7e?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b78c33d196d0e8e21eec7d2e93b220ee8c639838096e6657be89397cdbd2ee7e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b78c33d196d0e8e21eec7d2e93b220ee8c639838096e6657be89397cdbd2ee7e?s=96&d=mm&r=g","caption":"Sandy Walsh, RVT, CVPM"},"sameAs":["http:\/\/tvb.com"],"url":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/author\/swalsh\/"}]}},"_links":{"self":[{"href":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-json\/wp\/v2\/posts\/24842","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-json\/wp\/v2\/comments?post=24842"}],"version-history":[{"count":10,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-json\/wp\/v2\/posts\/24842\/revisions"}],"predecessor-version":[{"id":31228,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-json\/wp\/v2\/posts\/24842\/revisions\/31228"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-json\/wp\/v2\/media\/24801"}],"wp:attachment":[{"href":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-json\/wp\/v2\/media?parent=24842"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-json\/wp\/v2\/categories?post=24842"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-json\/wp\/v2\/tags?post=24842"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}